Veröffentlichungen 2005
Publikationen
1. Altmann A, Schulz RB, Glensch G, Eskerski H, Zitzmann S, Eisenhut M, Haberkorn U. Effects of Pax8 and TTF-1 Thyroid Transcription Factor Gene Transfer in Hepatoma Cells: Imaging of Functional Protein-Protein Interaction and Iodide Uptake. J Nucl Med 2005;46(5):831-839.
2. Askoxylakis V, Zitzmann S, Mier W, Graham K, Krämer S, von Wegner F, Fink RHA, Schwab M, Eisenhut M, Haberkorn U. Preclinical evaluation of the breast cancer cell binding peptide p160. Clin Cancer Res 2005;11(18):6705-12.
3. Bauer C, Bauder-Wuest U, Mier W, Haberkorn U, Eisenhut M. 131I -Labeled Peptides as Caspases Substrates for Apoptosis Imaging. J Nucl Med 2005;46:1066-1074.
4. Brix G, Schlicker A, Mier W, Peschke P, Bellemann ME. Biodistribution and Pharmacokinetics of the 19F-labeled Radiosensitizer 3-Aminobenzamide: Assessment with 19F MR Imaging. Magn Reson Imaging 2005;23:967-976.
5. Gassler N, Zhang C, Wenger T, Schnabel PA, Dienemann H, Debatin KM, Mattern J, Herr I. Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 2005;92(6):1084-8.
6. Haberkorn U, Mier W, Eisenhut M. Scintigraphic imaging of gene expression and gene transfer. Curr Med Chem 2005;12(7):779-94.
7. Haberkorn U. Einfluss molekularbiologischer Verfahren auf nuklearmedizinische Methoden. Influence of Molecularbiological Techniques upon Nuclearmedical Methods. Der Nuklearmediziner 2005;28:62-72.
8. Haberkorn U, Eisenhut M. Molecular imaging and therapy-a programme based on the development of new biomolecules. Eur J Nucl Med Mol Imaging 2005;32:1354-1359.
9. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Maecke HR, Eisenhut M, Debus J, Haberkorn U. Characterization of 68-Ga DOTA-D-Phe1-Tyr3-Octreotide Kinetics in Patients with Meningiomas. J Nucl Med 2005;46:763-769.
10. Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss LG, Eisenhut M, Kinscherf R, Haberkorn U. Gallium-68-DOTA-Albumin as a PET Blood-Pool Marker: Experimental Evaluation in vivo. Nucl Med Biol 2005;32:287-92.
11. Kiessling F, Le-Huu M, Kunert T, Thorn M, Vosseler S, Schmidt K, Hoffend J, Meinzer HP, Fusenig NE, Semmler W. Improved correlation of histological data with DCE MRI parameter maps by 3D reconstruction, reslicing and parameterization of the histological images. Eur Radiol 2005;15(6):1079-86.
12. Krause M, Hahnel S, Haberkorn U, Meinck HM. Dopa-responsive hemiparkinsonism due to midbrain Virchow-Robin spaces ? J Neurol 2005; 252:1555-1557.
13. Ludwig J, Mechtersheimer G, Haberkorn U, Nawroth P, Schilling T, Kasperk Ch. Oncogenic osteomalacia in a 49-year old female. Dtsch Med Wochenschr 2005;130(5):206-9.
14. Maecke HR, Hofmann M, Haberkorn U. Gallium-68 Labeled Peptides in Tumor Imaging. J Nucl Med 2005;46:172-178.
15. Mier W, Hoffend J, Kramer S, Schuhmacher J, Hull WE, Eisenhut M, Haberkorn U. Conjugation of DOTA using isolated phenolic active esters: labeling and biodistribution of albumin as blood pool marker. Bioconjug Chem 2005;16(1): 237-40.
16. Penuelas I, Haberkorn U, Yaghoubi S, Gambhir SS. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging 2005;32:384-403.
17. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Vorwald S, Eskerski H, Eisenhut M, Metz J, Kinscherf R, Haberkorn U. Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. Clin Cancer Res 2005;11:2132-2140.
18. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Schabitz WR. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005;115:2083-2098.
19. Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M. GRP Receptor-Targeted PET of a rat pancreas carcinoma xenograft in Nude Mice with a 68Gallium labeled Bombesin (6-14) analog. J Nucl Med 2005;46:691-699.
20. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, Lehnert T, Strauss LG, Herfarth C, Buchler MW. Prognostic significance of preoperative (18-F) Fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005;241(2):286-294.
21. Sorg BL, Hull WE, Kliem HC, Mier W, Wiessler M. Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy. Carbohydr Res 2005;340:181-189.
22. Thireou T, Kontaxakis G, Strauss LG, Dimitrakopoulou-Strauss A, Pavlopoulos S, Santos A. Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images. Med Biol Eng Comput. 2005;43(1):23-32.
23. Wolf M, Bauder-Wust U, Haberkorn U, Mier W, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: role of melanin, tyrosinase, intracellular pH and DNA interaction. Melanoma Res 2005;15(5):383-91.
24. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Krämer S, Altmann A, Eisenhut M, Haberkorn U. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res 2005;11:139-146.
25. Zitzmann S, Knapp EM, Mier W. Diagnostische Peptide: Spezifische Darstellung und Therapie von Krebserkrankungen. Laborwelt 2005;6:21-23.
26. Zitzmann S, Krämer S, Mier W, Mahmut M, Fleig J, Altmann A, Eisenhut M, Haberkorn U. Identification of a New Prostate-Specific Cyclic Peptide with the Bacterial FLiTRx System. J Nucl Med 2005;46:782-785.
Buchbeiträge
1. Cermáková M, Krämer S, Hoffend J, Eisenhut M, Haberkorn U, Mier W. Lipophilic derivatives of octreotate for the tumor selective transfection with liposomes. In: Flegel M, Fridkin M, Gilon C, Slaninova J (eds.) Proceedings of the Third International and Twenty-Eight European Peptide Symposium (2004). Kenes International, Switzerland, Prague, 2005; pp 585-586. ISBN 965-90833-0.0.
2. Graham KAN, Wang Q, Haberkorn U, Eisenhut M, Mier W. Synthesis and evaluation of intercalating peptide conjugates for the endoradiotherapy. In: Flegel M, Fridkin M, Gilon C, Slaninova J (eds.) Proceedings of the Third International and Twenty-Eight European Peptide Symposium (2004). Kenes International, Switzerland, Prague, 2005; pp 301-302. ISBN 965-90833-0.0.
3. Haberkorn U. Modulation of tracer accumulation in malignant tumors: gene expression, gene transfer and phage display. In: Ahrens ET (ed). Current Topics in Developmental Biology - In Vivo Cellular and Molecular Imaging. Vol. 70, 2005; pp 145-169. ISBN 0-12-153170-8.
4. Henze M, Hipp P. Chapter 3.3: Imaging – Nuclear Medicine. In: 3D Conformal Radiation Therapy - Multimedia Introduction to Methods and Techniques (Editors: Schlegel W, Mahr A), Springer Verlag, Berlin, Heidelberg, New York 2001; 2nd Edition 2005. ISBN 3540148841.
5. Kinscherf R, Bonaterra GA, Bodens A, Sauer R, Schlittenhardt D, Riedmüller K, Hildebrandt W, Dugi KA, Schmiedt W, Metz J. Besteht eine Korrelation zwischen proinflammatorischen Veränderungen in mononukleären Zellen des Blutes und in der arteriosklerotischen Gefäßwand? In: Heinle H, Schulte H, von Eckardstein HA (eds.) Stoffwechsel und Modifikation von Lipiden und Lipoproteinen. 2005; pp 83-87. ISBN 3-936423-04-0.
6. Kontaxakis G, Guerra P, Ohl R, Sachpazidis I, Strauss LG, Ortega F, Visvikis D, Diaz J, Cheze-Le Rest C, Dimitrakopoulou-Strauss A, Pan L, Santos A, Sakas G, Pozo MA. Redes telematicas transeuropeas para la tomografia por emision de positrones: el proyecto TENPET. In: Gomez Aguilera EJ, Hernando Perez ME, Caceres Taladriz C, Jimenez Fernandez S. (eds.) XXIII Congreso Anual de la Sociedad Espanola de Ingenieria Biomedica 2005; pp 215-218. ISBN 84-7402-325-4.
7. Mier W, Hoffend J, Haberkorn U, Eisenhut M. Current strategies in tumor-targeting. In: Gibson SB, Los M (eds). Apoptotic Pathways as Targets for Novel Therapies in Cancer & Other Diseases, Kluwer Academic Publ. Dordrecht, Boston, London 2005: pp 343-356. ISBN 0387233849.
8. Mier W, Eritja R, Haberkorn U, Eisenhut M. Tumor selective accumulation of PNA-oligomers conjugated to a somatostatin receptor affine peptide. In: Flegel M, Fridkin M, Gilon C, Slaninova J (eds.) Proceedings of the Third International and Twenty-Eight European Peptide Symposium (2004). Kenes International, Switzerland, Prague, 2005; pp 166-167. ISBN 965-90833-0.0.
9. Mier W, Graham KAN, Wang Q, Haberkorn U, Eisenhut M. Investigations into the C-terminal modification of somatostatin analogs. In: Flegel M, Fridkin M, Gilon C, Slaninova J (eds.) Proceedings of the Third International and Twenty-Eight European Peptide Symposium (2004). Kenes International, Switzerland, Prague, 2005; pp 299-300. ISBN 965-90833-0.0.
10. Riedmüller K, Kinscherf R, Kelber O, Weiser D, Metz J. Was können wir vom hypercholesterinämischen Kaninchen lernen? Über die Bedeutung proatherogener Serumparameter für das Screening atherosklerotischer Plaqueprozesse. In: Heinle H, Schulte H, von Eckardstein HA (eds.) Stoffwechsel und Modifikation von Lipiden und Lipoproteinen. 2005; pp 166-170. ISBN 3-936423-04-0.
11. Schönknecht P, Pantel J, Hunt A, Henze M, Strowitzki T, Schröder J. Chapter 13: Estrogens in Alzheimer’s Disease: A Clinical and Neurobiological Perspective. In: Estrogene Effects in Psychiatric Disorders (Editors: Bergemann N, Riecher-Rössler A). Springer Verlag Wien, New York 2005; pp 253-269. ISBN 3211404856.
12. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Krämer S, Altmann A, Eisenhut M, Haberkorn U. New peptide (DUP-1) targets prostate carcinoma in vivo. In: Flegel M, Fridkin M, Gilon C, Slaninova J. (eds.) Peptides 2004, Proceedings of the Third International and Twenty-Eight European Peptide Symposium. Kenes International, Switzerland, 2005; pp 449-450. ISBN 965-90833-0-0.